Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
09/2003
09/18/2003WO2003075857A2 Amino-methyl substituted tetracycline compounds
09/18/2003WO2003075847A2 NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
09/18/2003WO2003075834A2 Activated protein c formulations
09/18/2003WO2003075746A2 Methods for aneurysm repair
09/18/2003WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
09/18/2003WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
09/18/2003WO2003075670A1 Treatment and prevention of inflammatory disorders
09/18/2003WO2003053915A3 Compounds for the treatment of inflammatory disorders
09/18/2003WO2003053368A3 Chalcone derivatives and their use to treat diseases
09/18/2003WO2003051893A3 Improvements in pharmaceutical compositions
09/18/2003WO2003051807A3 Improvements in pharmaceutical compositions
09/18/2003WO2003037397A3 Drug eluting radially expandable tubular stented grafts
09/18/2003WO2003037363A3 Non-neurotoxic plasminogen activating factors for treating stroke
09/18/2003WO2003037308A3 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
09/18/2003WO2002100323A3 METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS
09/18/2003WO2002066646A3 Neurotransmission-associated proteins
09/18/2003WO2002064793A3 G protein-coupled receptor-like proteins and nucleics acids encoding same
09/18/2003WO2002062750A9 Cannabinoid receptor ligands
09/18/2003WO2002059308A3 Method of diagnosing and treating cartilage disorders
09/18/2003WO2002038557A9 Benzoylbenzofurane derivatives for treatment of cardiac arrhythmia
09/18/2003US20030176701 Di-or triaza-spiro [4,5] decane derivatives
09/18/2003US20030176688 Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide
09/18/2003US20030176686 Diagnosis, therapy; animal growth regulators; controlling cell differentiation; antiiinflammatory agents, antihistamines, Crohn's disease, anticancer agents, autoimmune disease
09/18/2003US20030176668 C-nitroso compounds and use thereof
09/18/2003US20030176651 Multiprotein-complex comprising a nmda receptor and uses thereof
09/18/2003US20030176650 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
09/18/2003US20030176642 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
09/18/2003US20030176511 Compositions and methods for treating cardiovascular disorders
09/18/2003US20030176509 Methods and products related to 16-HETE analogs
09/18/2003US20030176502 Pravastatin pharmaceutical formulations and methods of their use
09/18/2003US20030176501 For use in inhibiting HMG-CoA reductase; therapy and prophylaxis of hypercholesterolemia, atherosclerotic disease
09/18/2003US20030176499 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
09/18/2003US20030176497 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
09/18/2003US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof
09/18/2003US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer
09/18/2003US20030176487 For therapy and prophylaxis of disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative and metabolic disorders
09/18/2003US20030176481 Novel imidazole derivatives with anti-inflammatory activity
09/18/2003US20030176479 Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/18/2003US20030176476 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
09/18/2003US20030176469 Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors
09/18/2003US20030176465 Cyclic amino acid derivatives
09/18/2003US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally
09/18/2003US20030176457 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
09/18/2003US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin
09/18/2003US20030176453 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/18/2003US20030176451 Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound
09/18/2003US20030176448 Mitochondria protecting agents for treating mitochondria associated diseases
09/18/2003US20030176447 For therapy of cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease
09/18/2003US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
09/18/2003US20030176439 For therapy and prophylaxis of thromboembolic diseases and restenoses; reversible inhibitors of the blood clotting enzyme factor VIIa
09/18/2003US20030176429 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors
09/18/2003US20030176417 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds
09/18/2003US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors
09/18/2003US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors
09/18/2003US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
09/18/2003US20030176365 To improve cerebral function
09/18/2003US20030176349 Stable hypoxia inducible factor-1 alpha and method of use
09/18/2003US20030176339 For therapy and prophylaxis of diabetes, obesity, arteriosclerosis, hyperlipemia, hypertriglyceridemia, hypo-high density lipoproteinemia, hypoapolipoproteinemia A-I or nervous disorders
09/18/2003US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer
09/18/2003US20030176317 Stabilization of hypoxia inducible factor (HIF) alpha
09/18/2003US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction
09/18/2003US20030175934 Controlling cell differentiation, cell proliferation; anticancer agents
09/18/2003US20030175929 Recombinant human creatine kinase heterodimer with solution-stability
09/18/2003US20030175920 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
09/18/2003US20030175881 Nucleic acids encoding (poly) peptides having chips activity
09/18/2003US20030175847 Method of preparing heart muscle cells and method of searching for remedy for heart diseases
09/18/2003US20030175823 Method of screening remedy for heart failures
09/18/2003US20030175805 Comprises winglesslint 8D (Wnt-8D) polypeptides for treating asthma, nervous system, psychological, alzheimer, cancer, cardiomyopathies, lung and kidney disorders; wound healing agents; tissue engineering
09/18/2003US20030175764 Monitoring interleukin allelic expression to detect occlusive, fragile plaque, restenosive and atherscerotic disorders
09/18/2003US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents
09/18/2003US20030175361 Using selenium in combination with drugs used conventionally to treat psychiatric or neurological disorders
09/18/2003US20030175344 Comprising diuretic, beta blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist, calcium channel blocker, lipid-regulating agent, platelet function altering agent, serum homocysteine lowering agent
09/18/2003US20030175334 Phospholipid bodies and use thereof in medical treatment
09/18/2003US20030175276 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents
09/18/2003US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents
09/18/2003US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy
09/18/2003CA2482191A1 Spiro compounds with npy antagonistic activity
09/18/2003CA2481371A1 Use of ppar alpha agonists for the treatment of vascular and renal diseases
09/18/2003CA2479065A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists
09/18/2003CA2479036A1 Aryl substituted pyrimidines and the use thereof
09/18/2003CA2479016A1 Quinazoline compounds useful in therapy
09/18/2003CA2478945A1 Cyclic amides
09/18/2003CA2478942A1 An optically active pyridine derivative and a medicament containing the same
09/18/2003CA2478921A1 Novel chalcone derivatives and uses thereof
09/18/2003CA2478706A1 Oxo-azabicyclic compounds
09/18/2003CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity
09/18/2003CA2478652A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
09/18/2003CA2478599A1 Salts of nateglinide
09/18/2003CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
09/18/2003CA2478412A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same
09/18/2003CA2478342A1 Heterocyclic amide derivatives for the treatment of diabetes and other diseases
09/18/2003CA2478338A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478245A1 Treatment and prevention of inflammatory disorders
09/18/2003CA2478065A1 Macrocyclic compounds useful as pharmaceuticals
09/18/2003CA2477701A1 Controlled release dosage forms
09/18/2003CA2477577A1 Interferon beta-like molecules for treatment of stroke
09/18/2003CA2477256A1 Methods for aneurysm repair
09/18/2003CA2476031A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
09/18/2003CA2475738A1 Activated protein c formulations
1 ... 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 ... 1595